Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Tim Rogers who wrote (783)	11/25/2001 12:48:49 PM
From: Carter Berezay	Read Replies (1) \| Respond to of 792

Ever get the feeling there has been an information leak from MBI? I have my doubts the price and volume jump are just anticipatory buying alone. I think it could have been partially caused by the shorts bailing out in the last two trading days. I heard the rumor Canaccord is selling into any rally attempts. They preach longterm investing to their clients but those guys are very accomplished daytraders. They were probably net buyers in the $1.30 - $1.40 range. Somebody was putting a base under this stock. Events will show Canaccord and the other brokers are going to be on the right side of the market in the coming weeks/days. Canaccord and their ilk will be pushing their clients to buy and doing a lot of trades/crosses in the coming weeks. The money is not in the commissions any broker collects, it is in the successful daily trading of their house accounts, and volume is king. It is legalized profiteering built on the greed (and fear) of small individual investors. If they can make a 50-cent profit on any share, they will. And they just did! As always happens, Canaccord will run out of shares to sell from its house account. Then another broker (who has been accumulating at these current levels) will become the seller-of-the-day while Canaccord becomes a net buyer again. And the cycle repeats.... JMHO. Carter B.

To: Tim Rogers who wrote (783)	11/29/2001 4:15:15 PM
From: Tim Rogers	Read Replies (1) \| Respond to of 792

Attention Business Editors: Micrologix Biotech to Announce MBI 594AN Phase II Results Conference Call & Webcast Notification and Media Advisory Friday, November 30, 2001 - 9:00 a.m. ET; 6:00 a.m. PT Trading Symbol TSE: MBI US OTC: MGIXF VANCOUVER, Nov. 29 /CNW/ - Micrologix Biotech Inc. (TSE:MBI) announced today that it will host a conference call and webcast on Friday, November 30, 2001 to discuss the results from the Phase II clinical trial of MBI 594AN, a novel topical drug candidate under development for the treatment of acne. About Conference Call Micrologix's conference call will be held on Friday, November 30, 2001 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time). The dial in number to access the call is: 1-888-571-5411 or 416-646-3097, reservation number 156181. A replay of this call will be available from November 30 at 11:00 a.m. ET through December 10, 2001. The playback number is: 1-877-289-8525, reservation number 156181 or 416 640-1917, reservation number 156181. The Company will retain information about accessing the call on its website at mbiotech.com through the playback period. The call will also be webcast in live and archived versions from Micrologix's website at www.mbiotech.com. About Micrologix Micrologix Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of innovative drugs to treat or prevent various infectious diseases. The Company's current portfolio of anti- infective drug candidates is based on improved analogs of naturally occurring cationic peptides found in the host defense systems of most life forms. Micrologix currently has two drugs in clinical trials in the United States: MBI 226 for preventing catheter-related bloodstream infections (Phase III) and MBI 594AN for treating acne (Phase II). The Company's common shares are included in the TSE 300 Composite Index. -30- For further information: Investor & Media Relations Contacts: Jonathan Burke, Micrologix Biotech Inc., Telephone: (604) 221-9666, Toll-Free: 1-800-665-1968, E-mail: jburke@mbiotech.com; Marla Gale, Fleishman-Hillard Canada Inc., Telephone: (416) 214-0701, Fax: (416) 214-0720, E-mail: galem@fleishman.com; Website www.mbiotech.com